12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $12M | -$54000 | 99.2% | -398.8% | 0.3% | -0.1% | — | — | $968000 |
| 2024 | $12M | -$39250 | 0.0% | -263.8% | -0.6% | -0.1% | -$29M | — | $8M |
| 2023 | $10M | -$41900 | 0.0% | -351.3% | -0.9% | -0.1% | — | — | $6M |
| 2022 | $12M | -$48400 | 0.0% | -287.8% | 3.6% | -0.1% | -$33M | — | $5M |
| 2021 | $4M | -$52600 | 0.0% | -939.1% | -0.4% | -0.1% | -$35M | — | $17M |
| 2020 | $9M | -$34M | 0.0% | -283.9% | -196.5% | -78.9% | -$15M | — | $8M |
| 2019 | $6M | -$39M | 0.0% | -501.3% | -361.1% | -105.8% | — | — | $3M |
| 2018 | $4M | -$32M | 0.0% | -698.0% | — | -78.3% | -$23M | — | $3M |
| 2017 | $4M | -$22M | 0.0% | -785.3% | — | -50.4% | — | $13M | $520698 |
| 2016 | $141523 | -$15M | 0.0% | -9599.8% | — | -413.5% | -$15M | $4M | $950979 |
| 2015 | $258381 | -$16M | 0.0% | -4816.7% | — | -131.3% | — | $6M | $8M |
| 2014 | $0 | -$9M | — | — | — | -194.8% | — | — | $845192 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $1M | -$13M | 15.8% | -620.2% | -260.2% | -37.4% | — | — | $4M |
| Mar '26 | $20M | $9M | 94.3% | 50.2% | -55.4% | 23.3% | — | — | $7M |
| Dec '25 | $3M | -$23M | 32.0% | -656.6% | 124.1% | -60.5% | — | — | $968000 |
| Sep '25 | $3M | -$10M | 82.7% | -234.8% | -221.3% | -19.5% | — | — | $4M |
| Jun '25 | $3M | -$11M | 82.3% | -268.8% | -153.5% | -21.9% | — | — | $2M |
| Mar '25 | $2M | -$11M | 76.7% | -425.5% | -1276.6% | -20.6% | — | — | $6M |
| Dec '24 | $4M | -$10M | 84.1% | -232.5% | -157.6% | -19.2% | -$8M | — | $8M |
| Sep '24 | $3M | -$10M | 82.6% | -233.7% | -76.5% | -17.1% | -$6M | — | $13M |
| Jun '24 | $3M | -$10M | 84.3% | -264.5% | -58.1% | -15.7% | — | — | $16M |
| Mar '24 | $2M | -$9M | 81.7% | -349.4% | -79.3% | -16.9% | — | — | $12M |
| Dec '23 | $2M | -$9M | 70.1% | -328.6% | -190.1% | -18.3% | — | — | $6M |
| Sep '23 | $3M | -$8M | 81.7% | -312.4% | -558.2% | -17.4% | -$7M | — | $3M |
| Jun '23 | — | -$12M | — | — | -210.8% | -23.6% | -$9M | — | $9M |
| Mar '23 | — | -$12M | — | — | -161.8% | -21.8% | -$10M | — | $14M |
| Dec '22 | — | -$8M | — | — | 605.7% | -17.3% | -$6M | — | $5M |
| Sep '22 | — | -$13M | — | — | -350.3% | -24.6% | -$9M | — | $11M |
| Jun '22 | — | -$9M | — | — | -340.7% | -18.8% | — | — | $9M |
| Mar '22 | — | -$18M | — | — | -224.0% | -34.3% | — | — | $17M |
| Dec '21 | — | -$14M | — | — | -120.8% | -26.9% | -$9M | — | $17M |
| Sep '21 | — | -$12M | — | — | -56.6% | -20.6% | -$9M | — | $12M |
How the market has priced JAGX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Jaguar Health, Inc.'s revenue has grown 4.2% per year. These are computed facts, not advice.
As of FY2025, Jaguar Health, Inc. reported — of total debt against $968000 of cash; operating income covered interest expense -685.2×.
In FY2025, gross margin was 99.2%, operating margin -398.8%, and net margin -0.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.